The maximum tumour length in biopsy cores as a predictor of outcome after radical prostatectomy

BJU International

Volumn 101, Issue 2, 2008, Pages 175-180

  Hayashi, Norihiro ^a   Urashima, Mitsuyoshi ^a   Kuruma, Hidetoshi ^a   Arai, Yoichi ^b   Kuwao, Sadahito ^c   Iwamura, Masatsugu ^d   Egawa, Shin ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Higashiyamato Hospital   (Japan)

^d KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Biopsy; Maximum tumour length; Prognosis; Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER INVASION; CANCER LOCALIZATION; CORRELATION ANALYSIS; DEATH; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PHENOTYPE; POSTOPERATIVE PERIOD; PREDICTOR VARIABLE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; SEMINAL VESICLE; TUMOR BIOPSY; UNIVARIATE ANALYSIS;

AGED; BIOPSY, NEEDLE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 37349121046     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.07189.x     Document Type: Article

References (19)

1. King CR, Patel DA, Terris MK. Prostate biopsy volume indices do not predict for significant Gleason upgrading. Am J Clin Oncol 2005 28 : 125 9
2. Mizuno R, Nakashima J, Mukai M et al. Maximum tumor diameter is a simple and valuable index associated with the local extent of disease in clinically localized prostate cancer. Int J Urol 2006 13 : 951 5
3. Naya Y, Babaian RJ. The predictors of pelvic lymph node metastasis at radical retropubic prostatectomy. J Urol 2003 170 : 2306 10
4. Naya Y, Slaton JW, Troncoso P, Okihara K, Babaian RJ. Tumor length and location of cancer on biopsy predict for side specific extraprostatic cancer extension. J Urol 2004 171 : 1093 7
5. Kattan MW, Eastham JA, Wheeler TM et al. Counseling men with prostate cancer. a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 2003 170 : 1792 7
6. Stephenson AJ, Scardino PT, Eastham JA et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006 98 : 715 7
7. Eichelberger LE, Koch MO, Eble JN, Ulbright TM, Juliar BE, Cheng L. Maximum tumor diameter is an independent predictor of prostate-specific antigen recurrence in prostate cancer. Mod Pathol 2005 18 : 886 90
8. Renshaw AA, Richie JP, Loughlin KR, Jiroutek M, Chung A, D'Amico AV. Maximum diameter of prostatic carcinoma is a simple, inexpensive, and independent predictor of prostate-specific antigen failure in radical prostatectomy specimens. Validation in a cohort of 434 patients. Am J Clin Pathol 1999 111 : 641 4
9. Sengupta S, Myers RP, Slezak JM, Bergstralh EJ, Zincke H, Blute ML. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 2005 174 : 2191 6
10. Matsumoto K, Egawa S, Satoh T, Kuruma H, Yanagisawa N, Baba S. Computer simulated additional deep apical biopsy enhances cancer detection in palpably benign prostate gland. Int J Urol 2006 13 : 1290 5
11. Egawa S, Matsui Y, Matsumoto K et al. Impact of biochemical failure on long-term clinical outcome after radical prostatectomy for prostate cancer in Japan. Prostate Cancer Prostatic Dis 2004 7 : 152 7
12. Machida T, Ohishi Y, Wada T et al. [Clinical evaluation of a new kit (IMX PA Dainapack) for detection of serum prostate specific antigen]. Hinyokika Kiyo 1993 39 : 977 84
13. Sobin L, Wittekind CH. TNM Classification of Malignant Tumors, 5th edn. New York : Wiley and Sons, 1997
14. Egawa S, Takashima R, Matsumoto K, Mizoguchi H, Kuwao S, Baba S. Infrequent involvement of the anterior base in low-risk patients with clinically localized prostate cancer and its possible significance in definitive radiation therapy. Jap J Clin Oncol 2000 30 : 126 30
15. Japanese Urological Association and The Japanese Pathological Society. General Rules for Clinical and Pathological Studies on Prostatic cancer. 2001
16. Freedland SJ, Humphreys EB, Mangold LA et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005 294 : 433 9
17. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999 281 : 1591 7
18. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. New Eng J Med 2004 351 : 125 35
19. Haese A, Graefen M, Steuber T et al. Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies. J Urol 2003 170 : 2269 73